Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
KMT2A (Lysine Methyltransferase 2A)
i
Other names:
KMT2A, Lysine Methyltransferase 2A, Histone-Lysine N-Methyltransferase 2A, CXXC7, TRX1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila), Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Lysine N-Methyltransferase 2A, Zinc Finger Protein HRX, Trithorax-Like Protein, HTRX1, MLL1A, MLL1, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog), Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Mixed Lineage Leukemia 1, WDSTS, ALL1, HTRX
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4297
Related tests:
‹
AVENIO Tumor Tissue CGP Kit
Altera
Archer® VariantPlex® Myeloid panel
Labcorp® Plasma Complete™
MLL (KMT2A) Breakapart Fish Probe Kit
OncoSTRAT&GO
SureSeq™ Myeloid Fusion Panel
SureSeq™ Myeloid Plus Panel
SureSeq™ Pan-Myeloid Panel
TruSight Myeloid Sequencing Panel
AVENIO Tumor Tissue CGP Kit
Altera
Archer® VariantPlex® Myeloid panel
Labcorp® Plasma Complete™
MLL (KMT2A) Breakapart Fish Probe Kit
OncoSTRAT&GO
SureSeq™ Myeloid Fusion Panel
SureSeq™ Myeloid Plus Panel
SureSeq™ Pan-Myeloid Panel
TruSight Myeloid Sequencing Panel
›
Associations
(31)
News
Trials
VERI cancer hierarchy
Reset Filters
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
revumenib
Sensitive: B - Late Trials
revumenib
Sensitive
:
B
revumenib
Sensitive: B - Late Trials
revumenib
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
DSP-5336
Sensitive: B - Late Trials
DSP-5336
Sensitive
:
B
DSP-5336
Sensitive: B - Late Trials
DSP-5336
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KMT2A-PTD
Acute Myelogenous Leukemia
KMT2A-PTD
Acute Myelogenous Leukemia
cytarabine + decitabine + vorinostat
Sensitive: C3 – Early Trials
cytarabine + decitabine + vorinostat
Sensitive
:
C3
cytarabine + decitabine + vorinostat
Sensitive: C3 – Early Trials
cytarabine + decitabine + vorinostat
Sensitive
:
C3
KMT2A mutation
Solid Tumor
KMT2A mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
KMT2A rearrangement + CD19 positive
Acute Lymphocytic Leukemia
KMT2A rearrangement + CD19 positive
Acute Lymphocytic Leukemia
tisagenlecleucel-T
Sensitive: C3 – Early Trials
tisagenlecleucel-T
Sensitive
:
C3
tisagenlecleucel-T
Sensitive: C3 – Early Trials
tisagenlecleucel-T
Sensitive
:
C3
KMT2A rearrangement + CD19 positive
Acute Lymphocytic Leukemia
KMT2A rearrangement + CD19 positive
Acute Lymphocytic Leukemia
CD19-targeted CAR-T immunotherapy
Sensitive: C3 – Early Trials
CD19-targeted CAR-T immunotherapy
Sensitive
:
C3
CD19-targeted CAR-T immunotherapy
Sensitive: C3 – Early Trials
CD19-targeted CAR-T immunotherapy
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
KMT2A rearrangement + NPM1 mutation
Acute Myelogenous Leukemia
KMT2A rearrangement + NPM1 mutation
Acute Myelogenous Leukemia
revumenib
Sensitive: C3 – Early Trials
revumenib
Sensitive
:
C3
revumenib
Sensitive: C3 – Early Trials
revumenib
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax + sunitinib + I-BET151
Sensitive: C3 – Early Trials
venetoclax + sunitinib + I-BET151
Sensitive
:
C3
venetoclax + sunitinib + I-BET151
Sensitive: C3 – Early Trials
venetoclax + sunitinib + I-BET151
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax + revumenib
Sensitive: C3 – Early Trials
venetoclax + revumenib
Sensitive
:
C3
venetoclax + revumenib
Sensitive: C3 – Early Trials
venetoclax + revumenib
Sensitive
:
C3
KMT2A mutation
Leukemia
KMT2A mutation
Leukemia
JNJ-6617
Sensitive: C3 – Early Trials
JNJ-6617
Sensitive
:
C3
JNJ-6617
Sensitive: C3 – Early Trials
JNJ-6617
Sensitive
:
C3
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive: C3 – Early Trials
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive
:
C3
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive: C3 – Early Trials
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive
:
C3
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
Chr t(3;11) + KMT2A-LARS2 fusion
Acute Lymphocytic Leukemia
Chr t(3;11) + KMT2A-LARS2 fusion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C4 – Case Studies
blinatumomab
Sensitive
:
C4
blinatumomab
Sensitive: C4 – Case Studies
blinatumomab
Sensitive
:
C4
KMT2A-AFF1 fusion
Acute Lymphocytic Leukemia
KMT2A-AFF1 fusion
Acute Lymphocytic Leukemia
amlexanox
Sensitive: D – Preclinical
amlexanox
Sensitive
:
D
amlexanox
Sensitive: D – Preclinical
amlexanox
Sensitive
:
D
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
DS-1594
Sensitive: D – Preclinical
DS-1594
Sensitive
:
D
DS-1594
Sensitive: D – Preclinical
DS-1594
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
KMT2A expression
Acute Myelogenous Leukemia
KMT2A expression
Acute Myelogenous Leukemia
revumenib
Sensitive: D – Preclinical
revumenib
Sensitive
:
D
revumenib
Sensitive: D – Preclinical
revumenib
Sensitive
:
D
KMT2A expression
Acute Myelogenous Leukemia
KMT2A expression
Acute Myelogenous Leukemia
VTP-50469
Sensitive: D – Preclinical
VTP-50469
Sensitive
:
D
VTP-50469
Sensitive: D – Preclinical
VTP-50469
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
KMT2A rearrangement + RAS mutation
B Acute Lymphoblastic Leukemia
KMT2A rearrangement + RAS mutation
B Acute Lymphoblastic Leukemia
selumetinib + revumenib
Sensitive: D – Preclinical
selumetinib + revumenib
Sensitive
:
D
selumetinib + revumenib
Sensitive: D – Preclinical
selumetinib + revumenib
Sensitive
:
D
KMT2A rearrangement + RAS mutation
Acute Myelogenous Leukemia
KMT2A rearrangement + RAS mutation
Acute Myelogenous Leukemia
selumetinib + revumenib
Sensitive: D – Preclinical
selumetinib + revumenib
Sensitive
:
D
selumetinib + revumenib
Sensitive: D – Preclinical
selumetinib + revumenib
Sensitive
:
D
PTPRC positive + KMT2A rearrangement
Acute Myelogenous Leukemia
PTPRC positive + KMT2A rearrangement
Acute Myelogenous Leukemia
SGR-2921
Sensitive: D – Preclinical
SGR-2921
Sensitive
:
D
SGR-2921
Sensitive: D – Preclinical
SGR-2921
Sensitive
:
D
KMT2A mutation
Acute Myelogenous Leukemia
KMT2A mutation
Acute Myelogenous Leukemia
venetoclax + JNJ-6617
Sensitive: D – Preclinical
venetoclax + JNJ-6617
Sensitive
:
D
venetoclax + JNJ-6617
Sensitive: D – Preclinical
venetoclax + JNJ-6617
Sensitive
:
D
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
revumenib + ORY-1001
Sensitive: D – Preclinical
revumenib + ORY-1001
Sensitive
:
D
revumenib + ORY-1001
Sensitive: D – Preclinical
revumenib + ORY-1001
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login